Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Any planned or submitted questions for the 12.4 call?

<< Previous

Bullboard Posts

Next >>

Comment by N0taP00pon Dec 02, 2024 9:53pm

244 Views

Post# 36341951

RE:RE:Any planned or submitted questions for the 12.4 call?

@Kayz88: This is the ONLY really important question. If we get a clear answer to this, everything else is much clearer. Every PP investor will want to know this. If we get an answer that is open to interpretation, they lose whatever little credibility they had.

Kayz88 wrote: Why did the preBTD get rejected?
Given it took a full year before resubmission last time, what is the likelihood of that happening again where we have to wait till end of 2025 before we submit a preBTD?
How confident are we that we will be able to submit a BTD application for a Q1 2025 approval?

<< Previous

Bullboard Posts

Next >>

Critical materials crisis: Diversifying away from China’s monopoly